Rak płuca- co możemy zaoferować naszym pacjentom?
PDF (Język Polski)

How to Cite

Karolak, A. (2018). Rak płuca- co możemy zaoferować naszym pacjentom?. Letters in Oncology Science, 15(2), 66-70. https://doi.org/10.21641/los.15.2.75


The number of people suffering from lung cancer continues to grow. During the 36th ESTRO conference, the treatment options for this cancer were presented. Nuclear medicine plays an important role in treatment. Thanks to this method, the size and area of the tumor can be precisely determined. On the other hand, radiotherapy alone requires the integration of a multidisciplinary team to be able to initiate patient therapy. In order to be able to start a patient's therapy, radiotherapy requires a multidisciplinary integration of whole team. ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) have provided guidelines that allow proper qualification of the patient for the type of treatment. The guidelines presented on the basis of ESTRO ACROP involved the equipment and its capabilities that can be used for radiotherapy of patients with lung cancer.

PDF (Język Polski)


Focus on lung cancer: What a radiotherapy department should offer their patients M. Guckenberger , University Hospital Zürich, Department of Radiation Oncology, Zurich, Switzerland

PET/CT artefacts for RT planning A. Santos, Hospital Cuf Descobertas- S.A.

Vincent T. DeVita, Theodore S. Lawrence, Steven A. Rosenberg: Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology. Wyd. 8. Lippincott Williams & Wilkins, 2008. ISBN 978-0-7817-7207-5

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2nd ESMO Consensus Conference on Lung Cancer: `early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.


Download data is not yet available.